Zomedica aims to specialize in pet pharma


The Ann Arbor startup, which is in the early stages of developing drugs for cats, dogs and horses, announced last week it has finished raising the first segment of a private offering of $15 million Canadian, or the equivalent of about $11.7 million U.S. The company is part of a growing array of startups seeking to develop drugs tailored to specific animals, rather than repurposing human drugs.